SYLVIA VALENZUELA: Open Payments
NPI 1578822680 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,365 in 53 payments from 11 companies in 2025. Trend: 2023 $992 · 2024 $1,992 · 2025 $1,365
Food & beverage: $1,338Education: $27
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $242 |
| Otsuka America Pharmaceutical, Inc. | 6 | $220 |
| E.R. Squibb & Sons, L.L.C. | 5 | $168 |
| ABBVIE INC. | 6 | $157 |
| Abbott Laboratories | 9 | $140 |
| Braeburn Inc. | 1 | $122 |
| Alkermes, Inc. | 5 | $101 |
| Janssen Pharmaceuticals, Inc | 3 | $83 |
| Neurocrine BioSciences, Inc. | 2 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
Products named: COBENFY, VRAYLAR, REXULTI, AUSTEDO XR, BRIXADI, ETERNA, UZEDY, ARISTADA.
Industry payments across AZ — which companies pay providers there.
